Erratum: Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial [Open Forum Infectious Diseases, 2, 2, (2015)] Doi: 10.1093/ofid/ofv040;Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trial

Open Forum Infectious Diseases

Volumn 2, Issue 2, 2015, Pages

  Overton, Edgar Turner ^a   Stapleton, Jack ^b   Frank, Ian ^c   Hassler, Shawn ^d   Goepfert, Paul A ^a   Barker, David ^e   Wagner, Eva ^f   von Krempelhuber, Alfred ^g   Virgin, Garth ^h   Meyer, Thomas Peter ^f   Müller, Jutta ^f   Bädeker, Nicole ^f   Grünert, Robert ^f   Young, Philip ^f   Rösch, Siegfried ^f   Maclennan, Jane ^f   Arndtz Wiedemann, Nathaly ^f   Chaplin, Paul ^f  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Optimus Medical Group   (United States)

^e The CORE Center   (United States)

^f Bavarian Nordic GmbH   (Germany)

^g GLAXOSMITHKLINE   (Germany)

^h Vifor (International) Inc   (Switzerland)

Author keywords

HIV infection; Immunocompromised; MVA; Smallpox; Vaccination

Indexed keywords

MODIFIED VACCINIA ANKARA BAVARIAN NORDIC SMALLPOX VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION; VIRUS NEUTRALIZATION; VOMITING;

EID: 84978328509     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv183     Document Type: Erratum

References (30)

1. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980; 303:1263-73.
2. Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis 2003; 26:423-30.
3. Gaudioso J, Brooks TF, Furukawa, Lavanchy DO, Friedman D, Heegaard ED. Likelihood of Smallpox Recurrence. J Bioterr Biodef 2011; 2:106. doi: 10.4172/2157-2526.1000106.
4. Goldstein JA, NeffJM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55:342-7.
5. Lane JM, Ruben FL, NeffJM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303-9.
6. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. EffClin Pract 2002; 5:84-90.
7. Mayr A, Stickl H, Muller HK, et al. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 1978; 167:375-90.
8. Mayr A, Hochstein-Mintzel V, Stickl H. Passage history, properties, and use of attenuated vaccinia virus strain MVA. Infection 1975; 3:6-14.
9. Suter M, Meisinger-Henschel C, Tzatzaris M, et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 2009; 27:7442-50.
10. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24:2065-70.
11. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010; 28:1209-16.
12. Frey SE, Winokur PL, Salata RA, et al. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine 2013; 31:3025-33.
13. 50) in healthy vaccinia-naïve individuals. Vaccine 2014; 32:2732-9.
14. Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007; 25:8562-73.
15. Damon IK, Davidson WB, Hughes CM, et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009; 90:1962-6.
16. Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 2013; 207:749-58.
17. Sonnenburg F, Perona P, Darsow U, et al. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 2014; 32:5696-5702. PMID:25149431.
18. WalshRW, Wilck MB, Dominguez DJ, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013; 2007: 1888-97.
19. Acambis. ACAM2000 Smallpox Vaccines: Vaccines and Related Biological Products Advisory Committee (VRBPAC). Acambis Briefing Document, April 2007. 2007.
20. Elizaga ML, Vasan S, Marovich MA, et al. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review. PLoS One 2013; 8:e54407.
21. Landrum M, Dolan M. Routine vaccination in HIV-infected adults. Infect Dis Clin Pract 2008; 16:85-93.
22. Panchanathan V, Chaudhri G, Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol Cell Biol 2008; 86:80-6.
23. Benhnia MR, McCausland MM, Moyron J, et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 2009; 83:1201-15.
24. Moulton EA, Atkinson JP, Buller RM. Surviving mousepox infection requires the complement system. PLoS Pathog 2008; 4:e1000249.
25. Parker AK, Parker S, Yokoyama WM, et al. Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 2007; 81: 4070-9.
26. Karupiah G, Coupar B, Ramshaw I, et al. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol Cell Biol 1990; 68(Pt 5):325-33.
27. Benhnia MR, Maybeno M, Blum D, et al. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol 2013; 87: 1569-85.
28. Manischewitz J, King LR, Bleckwenn NA, et al. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis 2003; 188:440-8.
29. Findlay JW, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000; 21:1249-73.
30. Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171: 4969-73.